CLEC7A as a potential biomarker of atherosclerotic response to aspirin therapy: a multi-omics analysis.

Cai K, Chen D, Wang J, Bai J, Wang M, Guo J, Liu F, Duan JA, Su S

Open source

DOI
10.3389/fimmu.2026.1727020
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1727020,
  title = {CLEC7A as a potential biomarker of atherosclerotic response to aspirin therapy: a multi-omics analysis.},
  author = {Cai K and Chen D and Wang J and Bai J and Wang M and Guo J and Liu F and Duan JA and Su S},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1727020},
  url = {https://doi.org/10.3389/fimmu.2026.1727020}
}

RIS

TY  - JOUR
TI  - CLEC7A as a potential biomarker of atherosclerotic response to aspirin therapy: a multi-omics analysis.
AU  - Cai K
AU  - Chen D
AU  - Wang J
AU  - Bai J
AU  - Wang M
AU  - Guo J
AU  - Liu F
AU  - Duan JA
AU  - Su S
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1727020
UR  - https://doi.org/10.3389/fimmu.2026.1727020
ER  - 

APA

K, C., D, C., J, W., J, B., M, W., J, G., F, L., JA, D., & S, S. (2026). CLEC7A as a potential biomarker of atherosclerotic response to aspirin therapy: a multi-omics analysis.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1727020

Source records